{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:01:35Z","timestamp":1785132095697,"version":"3.55.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Statins are first-line therapeutic agents for metabolic syndrome, but their muscular adverse effects increase the metabolic burden in Type 2 diabetes mellitus (T2DM) and coronary heart disease (CHD). QiShenYiQi dropping pills (QSYQ), a compound Chinese medicine, exerts cardioprotective and metabolic regulatory effects. However, whether it is beneficial to gut microbiota dysbiosis and statin-associated muscle symptoms (SAMS) remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The disease model with T2DM complicated with CHD was established in APOE\n                      <jats:sup>\u2212\/\u2212<\/jats:sup>\n                      mice. The mice were randomly divided into normal control (NC), disease model (DM), Simvastatin + Fenofibrate (SF), Simvastatin + Fenofibrate + QSYQ (SFQ), and Simvastatin + Fenofibrate + Trimetazidine (SFT) groups, with 90 days of intervention. Using 16S rRNA sequencing, untargeted metabolomics, and transcriptomics, we investigated the regulatory effects and mechanism of QSYQ on unbalanced microbiota composition and SAMS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Combination therapy with QSYQ markedly ameliorated glycemic and lipid profiles in animals with comorbid T2DM and CHD, and outperformed other treatment strategies in preserving hepatic and skeletal muscle function. These beneficial effects may be correlated to the regulation of gut microbiota, glycolipid metabolites and associated gene expression, including inflammation-related genes, apoptosis-related genes, as well as antioxidant and energy metabolism-related genes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggested the potential value of QSYQ as a promising candidate for T2DM and CHD, attenuating the side effects of statins, providing a novel complementary strategy for clinical treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcell.2026.1837554","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:39:56Z","timestamp":1785130796000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of QiShenYiQi dropping pills on gut dysbiosis and statin-associated muscle symptoms in ApoE\u2212\/\u2212 mice with type 2 diabetes mellitus and coronary heart disease"],"prefix":"10.3389","volume":"14","author":[{"given":"Jingxin","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University","place":["Beijing, China"]},{"name":"Tasly Microcirculation Research Center, Peking University Health Science Center","place":["Beijing, China"]},{"name":"The Key Discipline for Integration of Chinese and Western Basic Medicine (Microcirculation) of the National Administration of Traditional Chinese Medicine","place":["Beijing, China"]},{"name":"Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People\u2019s Republic of China","place":["Beijing, China"]},{"name":"Beijing Microvascular Institute of Integration of Chinese and Western Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingzhen","family":"Shang","sequence":"additional","affiliation":[{"name":"Department of Clinical Trial Ward, Clinical Trial and Conversion Center, Shengjing Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University","place":["Beijing, China"]},{"name":"Tasly Microcirculation Research Center, Peking University Health Science Center","place":["Beijing, China"]},{"name":"The Key Discipline for Integration of Chinese and Western Basic Medicine (Microcirculation) of the National Administration of Traditional Chinese Medicine","place":["Beijing, China"]},{"name":"Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People\u2019s Republic of China","place":["Beijing, China"]},{"name":"Beijing Microvascular Institute of Integration of Chinese and Western Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyu","family":"Jiang","sequence":"additional","affiliation":[{"name":"Peking University Third Hospital, Peking University Health Science Center","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University","place":["Beijing, China"]},{"name":"Tasly Microcirculation Research Center, Peking University Health Science Center","place":["Beijing, China"]},{"name":"The Key Discipline for Integration of Chinese and Western Basic Medicine (Microcirculation) of the National Administration of Traditional Chinese Medicine","place":["Beijing, China"]},{"name":"Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People\u2019s Republic of China","place":["Beijing, China"]},{"name":"Beijing Microvascular Institute of Integration of Chinese and Western Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiancheng","family":"Xu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Acupuncture and Medicine Research of Ministry of Education, Nanjing University of Chinese Medicine","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yan","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University","place":["Beijing, China"]},{"name":"Tasly Microcirculation Research Center, Peking University Health Science Center","place":["Beijing, China"]},{"name":"The Key Discipline for Integration of Chinese and Western Basic Medicine (Microcirculation) of the National Administration of Traditional Chinese Medicine","place":["Beijing, China"]},{"name":"Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People\u2019s Republic of China","place":["Beijing, China"]},{"name":"Beijing Microvascular Institute of Integration of Chinese and Western Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University","place":["Beijing, China"]},{"name":"Tasly Microcirculation Research Center, Peking University Health Science Center","place":["Beijing, China"]},{"name":"The Key Discipline for Integration of Chinese and Western Basic Medicine (Microcirculation) of the National Administration of Traditional Chinese Medicine","place":["Beijing, China"]},{"name":"Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People\u2019s Republic of China","place":["Beijing, China"]},{"name":"Beijing Microvascular Institute of Integration of Chinese and Western Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"ITC81","DOI":"10.7326\/aitc202306200","article-title":"Dyslipidemia","volume":"176","author":"Arvanitis","year":"2023","journal-title":"Ann. Intern Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1111\/dom.16242","article-title":"Mechanisms of diabetic cardiomyopathy: focus on inflammation","volume":"27","author":"Bellemare","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1111\/dom.14046","article-title":"Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: the FIELD study","volume":"22","author":"Cao","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e13956","DOI":"10.1002\/advs.202513956","article-title":"Trigonelline improves metabolism and cardiac function of HFpEF mice Via gut microbiome alterations-mediated AMPK activation","volume":"13","author":"Cheng","year":"2026","journal-title":"Adv. Sci. (Weinh)"},{"key":"B5","first-page":"1012","volume-title":"Chinese Pharmacopoeia","year":"2025"},{"key":"B6","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/s2213-8587(24)00201-8","article-title":"Dysglycaemia screening and its prognostic impact in patients with coronary artery disease: experiences from the EUROASPIRE IV and V cohort studies","volume":"12","author":"Ferrannini","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.2337\/dc21-1977","article-title":"Fenofibrate and heart failure outcomes in patients with type 2 diabetes: analysis from ACCORD","volume":"45","author":"Ferreira","year":"2022","journal-title":"Diabetes Care"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1093\/jnci\/djj412","article-title":"Statins, fibrates, and melanoma risk: a systematic review and meta-analysis","volume":"98","author":"Freeman","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3390\/cells14131026","article-title":"The effects of different types of exercise on pulmonary inflammation and fibrosis in mice with type 2 diabetes mellitus","volume":"14","author":"Gao","year":"2025","journal-title":"Cells"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1527406","DOI":"10.3389\/fcvm.2025.1527406","article-title":"Sex-differences in endotoxemia and trimethylamine N-oxide according to the diet and type 2 diabetes status in coronary heart disease patients: from the CORDIOPREV study","volume":"12","author":"Garcia-Fernandez","year":"2025","journal-title":"Front. Cardiovasc Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"102590","DOI":"10.1016\/j.ebiom.2019.11.051","article-title":"Role of gut microbiota in type 2 diabetes pathophysiology","volume":"51","author":"Gurung","year":"2020","journal-title":"EBioMedicine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1141452","DOI":"10.3389\/fpubh.2023.1141452","article-title":"Projections of future burden of pharmacologically treated type 2 diabetes and associated life expectancies by income in Finland: a multi-state modeling study","volume":"11","author":"Guzman-Castillo","year":"2023","journal-title":"Front. Public Health"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2902351","DOI":"10.1155\/2016\/2902351","article-title":"An overview of murine high fat diet as a model for type 2 diabetes mellitus","volume":"2016","author":"Heydemann","year":"2016","journal-title":"J. Diabetes Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1007\/s00125-019-04973-z","article-title":"Fenofibrate increases very-long-chain sphingolipids and improves blood glucose homeostasis in NOD mice","volume":"62","author":"Holm","year":"2019","journal-title":"Diabetologia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10557-022-07405-0","article-title":"Comparative muscle tolerability of different types and intensities of statins: a network meta-analysis of double-blind randomized controlled trials","volume":"38","author":"Hou","year":"2024","journal-title":"Cardiovasc Drugs Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41467-023-35944-z","article-title":"Long-term statins administration exacerbates diabetic nephropathy via ectopic fat deposition in diabetic mice","volume":"14","author":"Huang","year":"2023","journal-title":"Nat. Commun."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s12276-022-00816-x","article-title":"Role of an unclassified lachnospiraceae in the pathogenesis of type 2 diabetes: a longitudinal study of the urine microbiome and metabolites","volume":"54","author":"Kim","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"EVIDra2400265","DOI":"10.1056\/evidra2400265","article-title":"Pharmacologic therapies for type 2 diabetes","volume":"4","author":"Kuo","year":"2025","journal-title":"NEJM Evid."},{"key":"B19","doi-asserted-by":"publisher","first-page":"6239829","DOI":"10.1155\/2022\/6239829","article-title":"Qishen yiqi dripping pill protects diabetic nephropathy by inhibiting the PI3K-AKT signaling pathways in rats","volume":"2022","author":"Li","year":"2022","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12933-025-02670-3","article-title":"Proteomic signatures of type 2 diabetes predict the incidence of coronary heart disease","volume":"24","author":"Li","year":"","journal-title":"Cardiovasc Diabetol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"156435","DOI":"10.1016\/j.phymed.2025.156435","article-title":"Proteomic analysis reveals QiShenYiQi pills ameliorates ischemia-induced heart failure through inhibition of mitochondrial fission","volume":"138","author":"Li","year":"","journal-title":"Phytomedicine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"757068","DOI":"10.3389\/fcell.2021.757068","article-title":"FSTL1-USP10-Notch1 signaling axis protects against cardiac dysfunction through inhibition of myocardial fibrosis in diabetic mice","volume":"9","author":"Lu","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-024-01951-9","article-title":"Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy","volume":"9","author":"Lu","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"46903","DOI":"10.31083\/rcm46903","article-title":"Statin-mediated modulation of Nrf2 signaling: mechanisms and therapeutic implications in atherosclerosis","volume":"27","author":"Marzoog","year":"2026","journal-title":"Rev. Cardiovasc Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1136\/gutjnl-2021-324053","article-title":"Host and gut microbial tryptophan metabolism and type 2 diabetes: an integrative analysis of host genetics, diet, gut microbiome and circulating metabolites in cohort studies","volume":"71","author":"Qi","year":"2022","journal-title":"Gut"},{"key":"B26","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","article-title":"Combination lipid-lowering therapy as first-line strategy in very high-risk patients","volume":"43","author":"Ray","year":"2022","journal-title":"Eur. Heart J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.kint.2020.07.038","article-title":"Statins, obesity, and the microbiome: a potential mechanism for the pleiotropic effects of Statin therapy","volume":"99","author":"Reichel","year":"2021","journal-title":"Kidney Int."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1093\/cvr\/cvac020","article-title":"Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications","volume":"118","author":"Ruscica","year":"2023","journal-title":"Cardiovasc Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.tem.2025.01.004","article-title":"Prediabetes remission to reduce the global burden of type 2 diabetes","volume":"36","author":"Sandforth","year":"2025","journal-title":"Trends Endocrinol. Metab."},{"key":"B30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00125-021-05592-3","article-title":"Prediabetes and risk of mortality, diabetes-related complications and comorbidities: umbrella review of meta-analyses of prospective studies","volume":"65","author":"Schlesinger","year":"2022","journal-title":"Diabetologia"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/eurheartj\/ehp556","article-title":"Statins, fibrates, and venous thromboembolism: a meta-analysis","volume":"31","author":"Squizzato","year":"2010","journal-title":"Eur. Heart J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1016\/j.jacc.2025.09.1602","article-title":"The heart-brain-metabolism axis in cardiovascular and neurologic disease","volume":"86","author":"Tardo","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12933-025-02819-0","article-title":"Associations of different insulin resistance-related indices with the incidence and progression trajectory of cardiometabolic multimorbidity: a prospective cohort study from UK biobank","volume":"24","author":"Tian","year":"2025","journal-title":"Cardiovasc Diabetol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"11687","DOI":"10.3390\/ijms222111687","article-title":"Statin-associated myopathy: Emphasis on mechanisms and targeted therapy","volume":"22","author":"Vinci","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41588-020-0637-y","article-title":"Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis","volume":"52","author":"Vujkovic","year":"2020","journal-title":"Nat. Genet."},{"key":"B36","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.mcna.2024.03.005","article-title":"Therapy for hyperlipidemia","volume":"108","author":"Wright","year":"2024","journal-title":"Med. Clin. North Am."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1038\/s41591-025-03642-6","article-title":"Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes","volume":"31","author":"Wu","year":"2025","journal-title":"Nat. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"157226","DOI":"10.1016\/j.phymed.2025.157226","article-title":"QiShenYiQi pills ameliorated aspirin and clopidogrel-induced gastric hemorrhage via multi-target regulation","volume":"147","author":"Zhan","year":"2025","journal-title":"Phytomedicine"},{"key":"B39","doi-asserted-by":"publisher","first-page":"104272","DOI":"10.1016\/j.phrs.2019.104272","article-title":"QiShenYiQi Pills\u00ae ameliorates ischemia\/reperfusion-induced myocardial fibrosis involving RP S19-mediated TGFbeta1\/Smads signaling pathway","volume":"146","author":"Zheng","year":"2019","journal-title":"Pharmacol. Res."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1837554\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:39:58Z","timestamp":1785130798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1837554\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":39,"alternative-id":["10.3389\/fcell.2026.1837554"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2026.1837554","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"article-number":"1837554"}}